Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

ARNA 4.09 +0.01 (0.25%)
price chart
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Short Interest Update
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), A drop of 1,185,971 shares or 4% was seen in the short interest of Arena Pharmaceuticals, Inc.. Even as the interest dropped from 29,624,866 shares on June 30,2015 to 28,438,895 shares on July 15,2015, the ...
Stock Update - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)  Vanguard Tribune
Morning Eye-Catchers: Arena Pharmaceuticals, Inc. (ARNA), CenturyLink, Inc ...  WallStreet Scope
12-Month Top Losers in Healthcare: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), latest closing price of $4.08 is at a discount to its 200-day moving average price of $4.47.
Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 ...
SAN DIEGO, July 29, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334 in ulcerative colitis.
Arena Pharmaceuticals (ARNA) Showing Signs Of Perilous Reversal Today
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Analyst Rating Update  Insider Trading Report
Arena Benefits From Celgene Buyout Of Receptos  Seeking Alpha
Will Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Surprise Analysts?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is next slated to report earnings for the current quarter on 2015-08-07. Brokerages covering the stock are currently expecting the firm to earn $-0.15 per share based on the 4 covering brokerages weighted into ...
Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells ...
Arena Pharmaceuticals Inc.'s shares have lost 7.37% in the last one month and 6.53% in the previous three months. However, the stock has gained 19.60% on YTD basis.
Analyst Price Target Update on Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): The mean estimate for the short term price target for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stands at $5.63 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $8 ...
Arena Pharmaceuticals Inc (NASDAQ:ARNA) in Spotlight
[EDGAR] Arena Pharmaceuticals Inc (NASDAQ:ARNA)(TREND ANALYSIS) On July 9, 2015, our Board of Directors appointed Jack Lief, our President and Chief Executive Officer, as our principal financial officer, and Jennifer K. Bielasz, our Vice President, ...
Top Biotech Stock Picking - Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX ...  Wall Street Observer
Will Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Surprise This Quarter?
Most recently for the quarter ending on 2015-03-31, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted a surprise factor of 28.57%.
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Large Outflow of Money  OTC Outlook
Company Shares of Arena Pharmaceuticals, Inc. Rally 4.9%
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rose by 4.9% in the past week and 1.81% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 2.43% and the outperformance increases to 1.01% for the last 4 weeks.